Healthcare Dec 04, 2021 09:35 AM (GMT+8) · EqualOcean
Today, the US FDA announced that it has approved MSD's heavy anti-PD-1 antibody therapy keytruda as an adjuvant therapy for patients with stage IIB and IIC melanoma (over 12 years old) who have undergone surgical resection. Previously, keytruda has been approved as an adjuvant therapy for patients with stage III melanoma.